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Objective 
The authors determined the impact of a positive cytotoxic crossmatch on the outcome of liver 
transplantation. 
Summary Background Data 
Liver allografts rarely undergo hyperacute rejection, but transplants performed across a positive 
cytotoxic crossmatch tend to follow a different clinical course, with higher intraoperative blood 
use, postoperative graft dysfunction, and, in some cases, graft loss. How this affects overall graft 
survival has not been determined. 
Methods 
The authors provide a retrospective analysis of 1520 liver transplants performed between 
November 1989 and December 1993, with a minimum follow-up of 1 year. All cases had a 
cytotoxic crossmatch using serum pretreated with dithiothreitol. 
Results 
There were 1390 negative crossmatch and 130 positive crossmatch cases. There was no 
difference in overall graft survival, although early survival rates were lower in the positive 
crossmatch group, with the maximum difference at 6 months: 0.76 (95% confidence interval, 
0.74-0.78) for a negative crossmatch versus 0.68 (95% confidence interval, 0.61-0.77) for a 
positive crossmatch. These differences become negligible by the 2-year mark. Using stepwise 
logistic regression, the authors identified seven variables independently associated with outcome: 
1) donor age, 2) donor gender, 3) prior liver transplant, 4) medical urgency status, 5) ischemia 
time, 6) indication for transplantation, and 7) primary immunosuppressant. 
Conclusions 
The cytotoxic crossmatch is not statistically associated with overall graft survival after liver 
transplantation. However, early failure rates are higher in the positive crossmatch cases, a 
difference that disappears by the second year. 
168 
Vol. 224.No. 2 
In the early days of kidney transplantation, it was es-
tablished that going across a positive cytotoxic cross-
match carried a prohibitively high risk of hyperacute re-
jection,I-3 making this a formal contraindication to the 
procedure. This has not been the case in liver transplan-
tation. From the beginning, it was observed that the liver 
is unusually resistant to hyperacute rejection,4-6 and an 
analysis of a large series from the cyclosporine era 
showed no difference in 2-year graft or patient survival 
when stratified according to crossmatch results,7 casting 
doubt on the relevance ofthis test in clinical liver trans-
plantation. However, this view began to change shortly 
thereafter. 
A report published in 1987 suggested that patients 
with antibodies directed against donor class I human leu-
kocyte antigens were more likely to have the vanishing 
bile duct syndrome develop,8 although most of these pa-
tients did not have these antibodies present before the 
transplant. Of the four that did, only one went on to have 
this form of chronic rejection.8 However, clear evidence 
of hyperacute rejection in recipients of liver allografts 
was reported over the next 2 years.9,lD 
Since then, a number of reports have appeared show-
ing that a positive cytotoxic crossmatch adversely affects 
liver transplantation, including graft and patient sur-
vival,II-14 although appropriate immunosuppressive 
therapy may abrogate this. IS Some authors, however, 
have challenged these observations,16 and we recently 
completed an analysis of risk factors in 419 patients un-
dergoing 462 liver transplants, where we found no asso-
ciation between a positive cytotoxic crossmatch and 
graft failure. 17 
Although there appears to be enough evidence that 
liver transplants performed across a positive cytotoxic 
crossmatch behave differently than those done in the ab-
sence of preformed antibodies, it remains unclear 
whether their overall outcome also differs. To try to an-
swer this important question, we carried out a multivar-
iate analysis of risk factors on 1520 adult liver 
transplants, all of which had a cytotoxic crossmatch us-
ing pretransplant serum treated with dithiothreitol 
(DTT).18-20 
MATERIAL AND METHODS 
Patient Population 
From November 5, 1989, to December 31, 1993, 1365 
adult patients underwent 1556 liver transplants at Pres-
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byterian University Hospital and the Veterans Admin-
istration Medical Center, Pittsburgh, PA; 1520 
transplants had a cytotoxic crossmatch with DTT and 
form the basis for this report. Cases were excluded from 
analysis if the liver was received as part of a multi visceral 
transplant that included intestine. All grafts were flushed 
with University of Wisconsin solution. The start of the 
study period coincides with the introduction of DTT 
pretreatment in our routine clinical practice. The ending 
date of the study was chosen to allow at least 1 year of 
follow-up (patients were observed until January 18, 
1995). 
Variables Studied and Endpoints 
Recipient variables were age, gender, indication for 
transplantation, UNOS status (United Network for Or-
gan Sharing classification, see Definitions), whether the 
transplant was primary or a retransplantation, the results 
of the cytotoxic crossmatch (with DTT), primary immu-
nosuppressive agent (e.g., tacrolimus, cyclosporine, or 
tacrolimus rescue), and whether the graft was an ABO 
blood group mismatch. 
Donor variables were age, gender, intensive care unit 
length of stay, harvest serum sodium, and total ischemia 
time. 
The primary endpoint was graft failure (see Defini-
tions), with cause of failure as a secondary endpoint. 
Definitions 
Definitions are as follows: 
1. Graft failure. Patient death or retransplantation at 
any time during follow-up. 
2. Medical urgency. UNOS 1: stable patient, waiting 
at home; UNOS 2: waiting at home, but requiring 
medical support; UNOS 3: unstable, in need of 
continuous hospitalization; and UNOS 4: requir-
ing life-support systems. We should note that this 
classification was changed on April 1, 1995, but we 
will use the classification that was in effect during 
the study period throughout this article. 
3. Total ischemia time. Time elapsed from aortic 
cross-clamping in the donor to portal or arterial re-
vascularization, or both, in the recipient. 
4. Indications. Refers to the primary diagnosis. In the 
case of a retransplantation, the diagnosis corre-
sponds to the cause of graft failure for the preceding 
liver allograft (Table 1). 
Cause of Graft Failure 
Causes of graft failure are as follows: 
1. Intraoperative. Cardiac arrest of any cause. 
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Category 
Autoimmune 
Cholestatic 
Alcoholic 
Hepatitic 
Metabolic 
Cryptogenic 
FHF 
PNF-ischemia 
HCC-cholangio 
Other malignancy 
Rejection, acute 
Rejection, chronic 
Technical 
Other 
Table 1. INDICATIONS FOR 
TRANSPLANTATION 
Diagnoses 
Autoimmune hepatitis 
PSC, PSC, cystic fibrosis, secondary biliary 
cirrhosis, and biliary atresia 
Ethanol-induced cirrhosis 
Hepatitis S, hepatitis C, etc. 
",-Antitrypsin deficiency, Wilson's disease, 
hemochromatosis, etc. 
All other etiologies of cirrhosis excluded 
Fulminant hepatic failure 
Primary non function and severe ischemic 
injury 
Hepatocellular carcinoma' and 
cholangiocarcinoma 
Secondary hepatic malignancies 
Self -explanatory 
Self -explanatory 
All technical complications 
Sudd-Chiari syndrome, benign tumors, etc. 
PBC = primary biliary cirrhosis; PSC = primary sclerosing cholangitis. 
, Excluding incidental tumors. 
2. Neurologic. Including, but not limited to, hemor-
rhagic or ischemic cerebrovascular accident, cen-
tral pontine myelinolysis, anoxic encephalopathy, 
and brain herniation. 
3. Cancer: de novo. Self-explanatory. 
4. Cancer: de novo, PTLD. Post-transplantation 
lymphoproliferative disease. 
5. Cancer: recurrent. Recurrent hepatobiliary or ex-
trahepatic cancer. 
6. Ischemic injury. Damage of the allograft, either 
before revascularization or after, that did not have 
a demonstrable immunologic etiology. 
7. Primary non-function (PNF). A graft with such 
poor initial function that retransplantation or 
death occurred within 2 weeks. No technical or 
immunologic causes of failure can be identified. 
8. Cardiac. Including, but not limited to, congestive 
heart failure, arrhythmias, and acute myocardial 
infarction. 
9. MODS. Multiple organ dysfunction syndrome 
(MODSf l without concomitant documented sep-
sis, and where the liver dysfunction cannot be at-
tributed to identifiable primary hepatic processes. 
10. Sepsis. MODS from a documented infection (also 
known as secondary MODS21 ). Includes bacterial, 
viral, and fungal etiologies. If a patient dies in the 
early post-transplant period with a documented 
infection, the decision to assign it to sepsis, PNF, 
or ischemic injury is made based on whether there 
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was poor function from the beginning (i.e., a 
death from sepsis in a graft that never functioned 
well is'coded as PNF or ischemic injury, as the 
case may be). An exception to this rule is the pa-
tient who goes into the transplant with an unrec-
ognized infection (e.g., positive blood cultures 
that are not reported back until after the surgery), 
in which case, it is assigned to sepsis regardless of 
the degree of initial dysfunction. 
11. Hepatitis: de novo. Includes hepatitis B, hepatitis 
C, cytomegalovirus, and adenovirus. 
12. Hepatitis: recurrent. Self-explanatory. 
13. Technical. Including, but not limited to, hepatic 
artery thrombosis and severe hepatic artery steno-
sis, portal vein thrombosis, caval stenosis, rup-
tured pseudoaneurysms, hemorrhage after liver 
biopsy, bile strictures (whether single or multiple), 
bile leaks, and bile cast syndrome. 
14. Rejection: acute. Including acute cellular and hu-
moral rejections.22 
15. Rejection: chronic. Occlusive arteriopathy or 
vanishing bile duct syndrome.22 
16. Unknown. Lost to follow-up, unc1assifiable. 
17. Other. Self-explanatory. 
When multiple processes were operating simulta-
neously, the assignment was made to the one considered 
to be most severe. 
Because the immediate cause of death in patients with 
liver failure is most commonly sepsis or MODS, the 
cause of graft failure was assigned to the liver pathology 
in those cases where the allograft dysfunction was the pri-
mary identifiable process (e.g., chronic rejection rather 
than pneumonia). 
If a patient died of sepsis in the face of ongoing acute 
rejection, the cause of failure was assigned to rejection, 
even if the liver function was not deemed to be severely 
impaired (we assumed a causal role for the increased im-
munosuppression required to treat the acute rejection). 
Exceptions to this rule were patients who first became 
septic and had the immunosuppression stopped and 
only then proceeded to reject. 
Cytotoxic Crossmatch 
Recipient sera were obtained immediately before 
starting the transplant operation, and an aliquot treated 
with DTT for 30 minutes to inactivate IgM antibod-
ies. 18-20 A T-cell crossmatch then was performed, with 
T lymphocytes isolated from donor lymph nodes, using 
the modified Amos technique.23 Crossmatches using 
untreated sera also were done, as a control, but we only 
consider the results of the crossmatch with DTT. The 
crossmatch results were scored in the following way: 
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Figure 1. Kaplan-Meier graft survival 
curves of liver transplantations done 
in the absence (n = 1390) or pres-
ence (n = 130) of a positive cytotoxic 
crossmatch. There is no difference in 
the overall results, but the early graft 
failure rate is higher in the positive 
crossmatch group. The numbers 
above and below the curves repre-
sent the grafts at risk in the negative 
and positive crossmatch groups, re-
spectively. 
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For the purposes of this study, we considered a cross-
match to be positive only if there was >50% cell kill. 
These results were not known prospectively. 
Statistical Analysis 
Continuous variables are presented as the mean ± 
standard deviation and categorical variables as propor-
tions. A two-tailed t test was used to test for differences 
between means. Pearson's chi square was used to test for 
differences among categorical variables. Exact p values 
were calculated for unbalanced or sparse contingency ta-
bles. If an association was found in variables containing 
more than two categories, a Tukey-Kramer multiple 
comparisons procedure on k groups with Bernoulli re-
sponses24 was used to identify the individual categories 
that were significantly different. The level of significance 
was set at 0.05. 
After the screening univariate analysis, those variables 
with a significance level of ~MKP were used in a stepwise 
logistic regression analysis25 to identify the variables that 
are independent predictors of outcome. In the case of 
categorical variables, preliminary univariate logistic re-
2 3 4 
Graft Survival (years) p = 0.65 
gression models were fit to determine what subcategories 
could be grouped together properly. Whenever possible, 
subcategories were considered individually only if they 
had ~ 100 observations (to obtain more accurate esti-
mates of the odds ratios). A similar preliminary analysis 
was carried out in the case of continuous variables to de-
termine if they were represented more appropriately as 
categorical variables. Models were fit using forward in-
clusion and backward elimination with a likelihood ratio 
test. The presence of an interaction between variables 
was tested by introducing appropriate multiplicative 
terms. A significance level of 0.1 was used in the stepwise 
procedure. 
Survival analysis was performed by means of the 
Kaplan-Meier method,26 with the log-rank test to com-
pare strata. All procedures were performed using SPSS 
(SPSS, Inc., Chicago, IL). 
RESULTS 
There were 1520 liver transplants performed in 1338 
patients. Of these, there were 1479 isolated livers; 18 liver 
and kidney; 11 liver and pancreatic islets; 9 liver with 
bone marrow infusion; 1 liver and heart; 1 liver, kidney, 
and heart; and 1 liver and pancreatic islet combined with 
a bone marrow infusion. There were 1267 (83.4%) pri-
mary transplants and 253 (16.6%) retransplantations. 
The crossmatch was negative in 1390 transplants and 
positive in 130. Eighteen cases in the positive crossmatch 
group were retransplantations, 6 of which had received 
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Table 2. CAUSE OF GRAFT FAILURE 
ACCORDING TO CROSSMATCH RESULTS 
Negative Positive 
Cause of Failure Count % Count % 
Acute rejection 9 1.8 4 8.3 
Chronic rejection 14 2.8 2 4.2 
PNF-ischemia 105 21.0 5 10.4 
Sepsis-MODS 136 27.2 19 39.6 
Technical 87 17.4 6 12.5 
PTLD 7 1.4 2.1 
Malignancy 40 8.0 1 2.1 
Hepatitis, recurrent 28 5.6 2 4.2 
Hepatitis, de novo 12 2.4 1 2.1 
Cardiac 17 3.4 0 0 
Neurologic 7 1.4 3 6.3 
Intraoperative 10 2.0 2 4.2 
Unknown 15 3.0 0 0 
Other 13 2.6 2 4.2 
PNF ~ primary nonfunction; MODS ~ multiple-organ dysfunction syndrome; PTLD 
~ post-transplantalion Iymphoproliferative disease. 
* No individual category reached statistical significance. 
OKT3 with the previous graft (four had a strong positive 
cross match and two a negative crossmatch with the pre-
vious graft). Because OKT3 therapy can interfere with 
lymphocytotoxicity assays,27 the analysis was conducted 
with and without these six cases, or excluding only the 
two cases with a previous negative crossmatch. The re-
sults essentially were identical, and all cases were in-
cluded in the final analysis. Figure 1 shows the Kaplan-
Meier graft survival curves, stratified according to the re-
sults of the crossmatch. There is no difference in overall 
graft survival; however, early survival is lower in the pos-
itive crossmatch group, with the difference being most 
pronounced at 6 months: 0.76 (95% confidence interval, 
0.74-0.78) for a negative crossmatch versus 0.68 (95% 
confidence interval, 0.61-0.77) for a positive cross-
match. These differences become negligible by the 2-year 
mark. 
There were 500 failed grafts with a negative cross-
match and 48 with a positive crossmatch; Table 2 sum-
marizes the causes of failure. Although no individual 
failure category reached statistical significance, there are 
several trends worth noting. Failures due to rejection, 
both acute and chronic, were more common in the posi-
tive crossmatch group, and so were those due to sepsis-
MODS. Interestingly, there were fewer failures due to 
PNF-ischemia than expected in the positive crossmatch 
group. The technical failures were analyzed separately; 
there was no difference among the causes of technical 
failure when stratifying according to crossmatch result. 
Specifically, failure rates due to hepatic artery thrombo-
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sis and biliary complications were identical (but the 
numbers are too small to make inferences). 
To investigate what factors are associated indepen-
dently with graft failure, we divided the transplants into 
two groups according to whether they were still function-
ing at the end of the follow-up period (group I, n = 972) 
or had failed (group II, n = 548). There were eight ABO 
mismatched grafts, five in group I and three in group II 
(p = 0.59). Recipient and donor characteristics are sum-
marized in Tables 3 and 4, respectively. 
There was no difference in terms of recipient age, gen-
der, and the results of the cytotoxic crossmatch. How-
ever, both groups differed regarding the fraction that was 
UNOS status 4, had a history of a prior liver transplant, 
or had cyclosporine-based immunosuppression. The in-
dications for transplantation also differed, with the fail-
ure group having proportionally fewer cases of chole-
static and autoimmune liver disease and a relative excess 
of PNF-ischemia (Table 3). Regarding donor character-
istics, failed grafts were more likely to come from older 
or female donors (Table 4). 
Table 3. RECIPIENT CHARACTERISTICS 
Group I Group" 
(n = 972) (n = 548) Significance 
Age(y) 49.1 ± 12.2 49.5 ± 12.3 P = 0.49 
Sex (M/F) 590/382 347/201 p = 0.31 
UNOS4(%) 46.6 58.4 P = 0.00001 
Prior transplant ('?'o) 11.7 2504 P < 0.00005 
Positive cross match (%) 8.4 8.8 p = 0.83 
Primary 
immunosuppressant (%) 
Tacrolimus 88.7 88.2 
Cyclosporine 2.2 4.9 
Tacrolimus rescue 9.1 6.9 p = 0.005 
Indication (%) 
Hepatitic 23.8 23.9 
Cholestatic 18.4 95 
Alcoholic 20.7 15.3 
Cryptogenic 7.7 9.5 
Autoimmune 4.3 1.5 
HCCcholangio 5.3 8.9 
Other malignancy 0.4 1.5 
PNF-ischemia 4.5 1004 
Metabolic 3.0 3.1 
FHF 1.9 2.0 
Chronic rejection 2.1 3.6 
Acute rejection 0.3 004 
Technical 3.9 5.8 
Other 3.7 4.6 P < 0.00005 
UNOS ~ United Network for Organ Sharing; HCC-cholangio = hepatocellular carci-
noma and cholangiocarcinoma; PNF = primary nonfunction; FHF ~ fulminant hepatic 
failure. 
Group I ~ grafts still functioning at the end of tile follow-up period; Group II = failed 
grafts. 
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Table 4. DONOR CHARACTERISTICS 
Group I Group II 
(n = 972) (n = 548) Significance 
Age(% >45y) 24.6 35.6 p = 0.00001 
Sex (% females) 30.6 40.3 P = 0.0001 
ICU length of stay (days) 4.1 ± 8.0 3.9 ± 3.9 p = 0.65 
Harvest serum sodium (%) 
<136 8.1 9.3 
136-145 31.0 29.4 
146-160 45.3 44.2 
>160 15.6 17.1 P = 0.71 
Ischemia time (hr) 13.8 ± 3.7 14.1±3.9 p = 0.22 
ICU ~ intensive care unit. 
Group I ~ grafts still functioning at the end of the follow-up period; Group II ~ failed 
grafts. 
The results of the multivariate analysis are summa-
rized in Table 5. As in our previous work, studying a 
smaller sample,17 we found that donor age and gender 
were associated independently with outcome. There was 
no evidence of an interaction between these two factors 
(i.e .. their effects were only additive). The odds offailure 
were more than twice as high for patients with a prior 
liver transplant and almost three times as high for those 
receiving cyclosporine-based immunosuppression (com-
pared with those receiving tacrolimus-based immuno-
suppression). Transplants performed on patients UNOS 
status 4 also carry a modest increase in the risk of failure 
(odds ratio 1.3), and for each additional 6 hours ofisch-
emia, the odds ratio is 1.27. 
Table 5 also lists the failure risk associated with differ-
ent indications for transplantation, using cholestatic as 
the reference category. The cholestatic group had the 
lowest risk of failure, followed by alcoholic cirrhosis, 
whereas at the other end of the spectrum, we find those 
patients transplanted for primary hepatobiliary malig-
nancies (HCC-cholangio). Transplants performed on pa-
tients UNOS status 4 or with a history of a previous liver 
transplant were more likely to fail because of sepsis-
MODS than from other causes (p < 0.05). No associa-
tion was found between other risk factors and graft fail-
ure categories. 
Because the early failure rate is higher in the positive 
crossmatch group, we then investigated whether the fac-
tors that are independently associated with early failure 
differ from those associated with overall failure. The 
transplants were divided into two groups: according to 
whether they functioned for more that 6 months (group 
Ie, n = 1146) or failed within this interval (group lIe, n = 
374). There were seven ABO-mismatched grafts in group 
Ie and one in group lIe (p = 0.37). Recipient and donor 
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characteristics are summarized in Tables 6 and 7, respec-
tively. 
There was no difference in recipient age and gender. 
Early failures were more likely to be associated with a 
history of prior liver transplant, UNOS status 4, and cy-
closporine-based immunosuppression. There also were 
proportionally more cases of PNF-ischemia among the 
early failure group. In contrast to the overall failures, 
however, early failures had a borderline association with 
the cytotoxic crossmatch (more likely to fail early with a 
positive crossmatch, p = 0.055; refer to Table 6). There 
were no differences between early and overall failures re-
garding donor characteristics, with both age and gender 
being associated with early failure (Table 7). 
Table 8 lists the results of the multivariate analysis. 
Except for the indication for transplantation, variables 
found to be associated independently with overall failure 
also were associated with early failure. This includes do-
nor gender, which in our previous study,17 in a smaller 
patient population, failed to reach significance in the 
early failure group. The cytotoxic crossmatch also was 
associated with early failure (odds ratio for a positive 
crossmatch: 1.5). 
DISCUSSION 
In contrast to the kidney,I-3 a positive cytotoxic cross-
match is not a contraindication to liver transplantation. 
This policy arose out of necessity, because of the short 
Table 5. VARIABLES INDEPENDENTLY 
ASSOCIATED WITH GRAFT FAILURE 
Odds Ratio 
Donor age (>45 y) 1.7 
Female donor sex 1.4 
Prior liver transplant 2.3 
UNOS4 1.3 
Ischemia time 1.27' 
Indication 
Cholestatic Reference 
Hepatitic 1.9 
Alcoholic 1.4 
Cryptogenic 2.2 
PNF·ischemia 2.0 
HCC-cholangio 3.6 
Other 1.5 
Primary immunosuppression 
Tacrolimus Reference 
Cyclosporine 2.8 
T acrolimus rescue 0.80 
95% CI 
1.3-2.1 
1.1-1.7 
15-3.5 
1.1-1.7 
1.1-1.5' 
1.3-2.8 
0.94-2.1 
1.3-3.6 
10-3.8 
2.2-6.0 
0.98-2.4 
1.5-5.1 
0.5-1.2 
CI ~ confidence interval; UNOS ~ United Network for organ sharing; PNF ~ primary 
nonfunction; HCC-cholangio ~ hepatocellular carcinoma and cholangiocarcinoma. 
, For each 6·hour increment in ischemia time. 
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Table 6. RECIPIENT CHARACTERISTICS: 
ANAL YSIS OF EARLY GRAFT FAILURES 
Group Ie Group lie 
(n = 1146) (n = 374) Significance 
Age (yr) 490± 12.250.1 ± 12.5 p=0.13 
Sex (M/F) 713/433 224/150 p = 0.42 
UNOS4 (%) 47.2 62.0 P < 0.00005 
Prior transplant (%) 12.6 29.1 P < 0.00005 
Positive crossmatch (%) 7.8 11.0 P = 0.055 
Primary immunosuppressant (%) 
Tacrolimus 88.5 88.8 
Cyclosporine 2.2 6.1 
Tacrolimus rescue 9.3 5.1 P = 0.00004 
Indication (%) 
Hepatitic 24.4 21.9 
Cholestatic 16.5 11.2 
Alcoholic 20.2 14.4 
Cryptogenic 7.9 9.6 
Autoimmune 3.8 1.9 
HCC-cholangio 6.9 5.9 
Other malignancy 0.9 0.5 
PNF-ischemia 4.6 12.8 
Metabolic 2.6 4.3 
FHF 1.7 2.7 
Chronic rejection 2.6 2.7 
Acute rejection 0.3 0.3 
Technical 3.9 6.7 
Other 3.7 5.1 P < 0.00005 
UNOS ~ United Network for Organ Sharing; HCC-cholangio ~ hepatocellular carci-
noma and cholangiocarcinoma; PNF = primary nonfunction; FHF ~ fulminant hepatic 
failure. 
Group Ie ~ grafts still functioning at the 6-month cut-off; Group lie = grafts that failed 
before the 6-month cut-off. 
preservation times initially allowed by the liver, and was 
bolstered by the observation that this organ is uniquely 
resistant to antibody-mediated rejection.4- 6 In fact, in an 
analysis of the largest series to come out of the cyclospor-
ine era, transplants done across a positive cytotoxic cros-
smatch were found to have a slightly better (albeit not 
statistically significant) survival than those done in the 
presence of a negative crossmatch.7 This led the authors 
to speculate whether preformed antibodies might actu-
ally have a protective or tolerogenic effect in liver trans-
plantation. 
We now know this is not the case. Although highly 
unusual, the liver can experience hyperacute rejec-
tion.9.1O,n Transplants carried out in the presence of pre-
formed antibodies tend to follow a different clinical 
course, with higher intraoperative blood use, postopera-
tive graft dysfunction, and, in some cases, graft loss. This 
seems to be more so for isoagglutinins29-31 than lympho-
cytotoxic antibodies. I I , 12.32 Biopsies of crossmatch-posi-
tive cases show a higher incidence of "preservation in-
jury" and acute cellular rejection than those of matched 
. - .. _-- .. _-_ ..... __ .. - ---_ .. _ .. _-_. __ ... __ . __ ..... _-_ ... ,---_ .. ,-_.-
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controls,12 and graft failure rates have been reported to 
be higher in presensitized patients. 11-14 
The results of our multivariate analysis, on the largest 
clinical series where the effect of the crossmatch has been 
studied, indicate that a positive cytotoxic crossmatch has 
no discernible effect on eventual graft survival. Although 
this may come as a surprise considering the growing lit-
erature stating otherwise, a careful look at the data begins 
to show the complexity of this issue. Using stepwise lo-
gistic regression, we found seven variables associated in-
dependently with outcome: 1) donor age, 2) donor gen-
der, 3) history of a prior liver transplant, 4) UNOS status 
4, 5) ischemia time, 6) indication for transplantation, 
and 7) primary immunosuppressant (Table 5). There 
was no association between donor serum sodium at the 
time of procurement and graft outcome, in contrast to 
recent reports,33,34 and the same can be said about the 
donor's length of stay in the intensive care unit. We re-
ported recently on the effects of donor age and gender, 
with grafts procured from women or donors older than 
45 years having a higher incidence of failure. 17 The cur-
rent study, conducted on a much larger sample, confirms 
these results. 
The adverse effect of increasing donor age had been 
surmised from the start of clinical liver transplantation, 
when a ceiling of 45 years was suggested for donor can-
didacy.35 Over the ensuing years, a number of reports 
appeared, suggesting that outcome was not affected by 
increasing donor age,36-38 presumably because of the liv-
er's resistance to senescence.39 However, we found re-
cently that livers from donors older than 60 years have 
only a 43% 2-year survival versus 71 % for the younger 
donors.4o A detailed analysis showed that the risk off ail-
ure, as a function of donor age, remains constant until 
age 45 and increases sharply after that. 17 
Table 7. DONOR CHARACTERISTICS: 
ANALYSIS OF EARL V GRAFT FAILURES 
Groupie Group lie 
(n = 1146) (n = 374) Significance 
Age (% >45 yr) 25.0 39.6 p<0.00005 
Sex (% females) 31.2 43.0 P = 0.00003 
ICU length of stay (days) 405 ± 7.7 3.87 ±3.5 P = 0.67 
Harvest serum sodium (%) 
<136 8.3 9.4 
136-145 31.5 27.0 
146-160 44.8 45.3 
>160 15.4 18.3 P = 0.37 
Ischemia time (hr) 13.8 ± 3.7 14.1 ±4.0 p = 0.3 
ICU = intensive care unit. 
Group Ie = grafts still functioning at the 6-month cut ·off; Group lie = grafts that failed 
before the 6-month cut-off. 
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Table 8. VARIABLES INDEPENDENTLY 
ASSOCIATED WITH EARLY GRAFT FAILURE 
Odds Ratio 
Donor age (>45 yr) 1.9 
Female donor sex 1.4 
Prior liver transplant 2.8 
UNOS 4 status 1.4 
Ischemia time 1.28" 
Positive crossmatch 1.5 
Primary immunosuppression 
Tacrolimus Reference 
Cyclosporine 3.5 
Tacrolimus rescue 0.5 
CI = confidence interval; UNOS = United Network for Organ Sharing . 
• For each 6-hour increment in ischemia time. 
95%CI 
1.4-2.5 
1.1-1.8 
1.9-3.7 
1.1-1.9 
1.05-1.6" 
0.96-2.2 
1.9-6.4 
0.3-0.9 
Grafts obtained from female donors show a modest 
degradation in survival (refer to Table 5), a finding we 
are at a loss to explain. Livers from female donors do 
slightly worse if given to male recipients than if given to 
female recipients (data not shown), but the difference in 
the risk of failure of a female-to-female versus a female-
to-male combination is small, and it is unclear whether 
the gender of the recipient is a significant factor. Because 
of this, and our desire to simplify the model, we only 
consider the gender of the donor as a risk factor. We 
found no association between donor-recipient gender 
combination and specific causes offailure. 
Risk factors such as a history of prior liver transplant, 
UNOS status 4, and ischemia time are well known.22,41-45 
Similarly, that the main indications for transplantation 
have different prognoses was recognized from the very 
beginning,22 although this study marks the first time that 
their risks are calculated while controlling for the effects 
of confounding variables. Not surprisingly, the choice of 
primary immunosuppressant also was found to be asso-
ciated with graft outcome, with grafts treated exclusively 
with cyclosporine-based immunosuppression being 
more likely to fail (odds ratio 2.8) than those treated ex-
clusively with tacrolimus-based immunosuppression. 
This observation suffers from all the limitations inherent 
in retrospective analyses, but it is supported by a wealth 
of evidence obtained by our group46-48 and others49-51 
that point toward the superiority of tacrolimus in liver 
transplantation. 
What is the significance, then, of a positive cytotoxic 
crossmatch? An answer is suggested in Figure 1, which 
shows that graft survival is lower in the early post-
transplant period in positive crossmatch cases, but the 
difference vanishes by the second year. Multivariate 
analysis also shows that crossmatch is associated with 
early outcome (i.e., within 6 months, refer to Table 8), 
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but not with overall outcome. Although it did not reach 
statistical significance, positive crossmatch grafts were 
more likely to fail because of rejection or sepsis-MODS 
(Table 2). Taken together, these observations support the 
idea that a positive cytotoxic crossmatch adversely im-
pacts liver transplant outcome, but the degree of back-
ground noise is still so high that its overall importance is 
masked. Therefore, with a positive crossmatch, we pay 
up front. This agrees with the findings of Takaya et al., II 
who showed lower I-year graft survival in positive cross-
match cases compared with a matched control group. 
Similar findings were reported by Katz et al. 13 in a small 
series. The durability of grafts that make it through the 
high risk early period may be explained by the change in 
the complement components of the recipient to predom-
inantly donor phenotype. In xenograft models, this alter-
ation in host environment has been shown to interdict 
hyperacute (humoral) rejection. 52 
Our results do stand in sharp contrast to those of Ni-
kaein et aI., 14 who recently reported overall lower patient 
and graft survivals when going across a positive cytotoxic 
crossmatch (448 negative and 34 positive). Besides our 
larger sample size, their study differs in several ways. 
Whereas we use a modified Amos technique,23 the Bay-
lor group reports using both standard NIH53 and anti-
human globulin (AHG)54 techniques. Unfortunately the 
authors do not state in their report how many patients 
were crossmatched with each technique, so it is not clear 
if this could explain our different findings. In the AHG 
technique, an antihuman Ig antibody is added to in-
crease the cytotoxic potential of lymphocyte-bound an-
tibody, making it not only a more sensitive method to 
detect low concentrations of complement fixing antibod-
ies, but also one that is capable of detecting antibodies 
that do not fix complement. 54 It has been suggested in 
the kidney transplant literature that AHG-dependent an-
tibodies will not cause immediate graft loss, but rather 
failures within the first few months; this effect seems to 
be primarily limited to retransplantations.55,56 Whether 
a similar mechanism could be operating in liver trans-
plantation remains to be determined. 
Another difference is that in the Baylor study, a posi-
tive crossmatch was defined as > 10% kill, and their ex-
clusion criteria included retransplants, patients treated 
with tacrolimus, and those dying within 1 week. 14 How-
ever, when we repeated our survival analysis excluding 
cases with a previous transplant, and using> 10% cell kill 
as the definition of a positive crossmatch, we still found 
no difference in overall survival (data not shown). Be-
cause almost 90% of our patients were treated with ta-
crolimus, we could not exclude them from the analysis, 
which brings up the question of whether our results are 
related to the different immunosuppressive regimens. 
Knowing the results of the crossmatch certainly is use-
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ful, because it helps identify a high-risk group that re-
quires special attention and, most likely, more aggressive 
immunosuppression. However, we disagree totally with 
the position that transplanting across a positive cytotoxic 
crossmatch is "inadvisable,"57 because the overall re-
suIts, at least in terms of graft failure rates, are indistin-
guishable. There is much interest, both on the part of 
society and that of practitioners, to be able to understand 
what factors determine the outcome ofliver transplanta-
tion and to use that information to maximize the benefit 
that can be derived from our chronically insufficient sup-
ply of organs. We have yet to reach that point, but a pic-
ture is starting to emerge, one that hints at the great com-
plexity of this problem. We do know enough already to 
state that, other than a few well-defined formal contrain-
dications, there probably is no single risk factor so influ-
ential that it could be used to preclude someone from 
transplantation. This decision will have to be made 
based on a consideration of how multiple risk factors act 
together. Determining how best to model these factors 
and their interactions will require a great deal of work. 
An example of this is the age of the donor, which in this 
study, we treated as a categorical variable, mostly for 
convenience of exposition. However, we have already 
shown that the risk associated with donor age does not 
go up abruptly and to a constant level (as a step function 
would) after 45 years. 17 Rather, the risk increases every 
year (after age 45), and this information should probably 
be included in the model, for example through a local 
regression procedure or a regression spline. 17 We should 
be alert to the misuse of certain statistical models, espe-
cially Cox proportional hazards. 58 As part of an ongoing 
study, we formally have tested the proportionality of 
hazards for variables that are associated with outcome 
and found that several of them (e.g., UNOS status, prior 
transplant, indications for transplantation) violate this 
crucial assumption (unpublished observations, 1995). If 
we are to use Cox regression, we must use an extension 
of the model designed to deal with nonproportional haz-
ards.59.6o 
In summary, we have studied the effect of a positive 
cytotoxic crossmatch on the outcome ofliver transplan-
tation. Although the graft failure rate is higher in the 
early post-transplant period when going across a positive 
cross match, the difference disappears by the second year. 
U sing multivariate analysis, we identified seven variables 
that are associated independently with outcome: 1) do-
nor age, 2) donor gender, 3) history of a prior liver 
transplant, 4) UNOS status 4, 5) ischemia time, 6) indi-
cation for transplantation, and 7) primary immunosup-
pressant. The results of the crossmatch should not be 
used to decide against transplantation, but they do iden-
tifya high-risk group of patients that requires special at-
Ann. Surg .• August 1996 
tention and, probably, more aggressive immunosuppres-
sion. 
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